48 Active Studies

Lupus Clinical Trials Near You

Also searched as: SLE, systemic lupus, lupus erythematosus clinical trials

Find 48 actively recruiting lupus research studies near you. Connect with study sites, check eligibility, and explore new treatment options.

48
Active Trials
162+
Locations
11,922
Participants Needed

Recruiting Studies

RecruitingNCT05843643

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult...

10 locations(Chandler, Flagstaff, Gilbert)
1,000 participants
AbbVie
View Study Details
RecruitingNCT06133972

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of t...

10 locations(Anniston, La Palma, Westlake Village)
550 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNCT04895241

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active...

10 locations(Homewood, Beverly Hills, Los Angeles)
540 participants
Biogen
View Study Details
RecruitingNCT04961567

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active...

10 locations(Birmingham, Glendale, Huntington Beach)
540 participants
Biogen
View Study Details
RecruitingNCT05617677

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population....

10 locations(Birmingham, Phoenix, Phoenix)
490 participants
Bristol-Myers Squibb
View Study Details
RecruitingNCT05620407

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population....

10 locations(Searcy, La Jolla, La Mesa)
490 participants
Bristol-Myers Squibb
View Study Details
RecruitingNCT05531565

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE). The study will focus on participants who have eithe...

10 locations(Anniston, Birmingham, Phoenix)
474 participants
Biogen
View Study Details
RecruitingNCT06015737

A 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with cutaneous lupus erythematosus (CLE)....

10 locations(Glendale, Phoenix, Covina)
460 participants
AstraZeneca
View Study Details
RecruitingNCT06617325

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of mo...

10 locations(Avondale, Chandler, Gilbert)
450 participants
UCB Biopharma SRL
View Study Details
RecruitingNCT05648500

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to severe symptoms. The main questions it aims to answer a...

10 locations(Fullerton, Huntington Park, Aurora)
420 participants
Viatris Innovation GmbH
View Study Details
RecruitingNCT05126277

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult p...

10 locations(Birmingham, La Palma, Los Angeles)
420 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNCT05672576

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to severe symptoms. The main questions it aims to answer ar...

10 locations(Tucson, La Jolla, Northridge)
420 participants
Viatris Innovation GmbH
View Study Details
RecruitingNCT05639114

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC)...

10 locations(Tucson, Burbank, La Jolla)
406 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNCT04829539

Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Chemotherapy

This phase III trial compares BBT-CI to HEAL for the reduction of insomnia in patients with stage I-IV cancer who are receiving cancer treatment. Cancer treatment can cause side effects such as sleep ...

10 locations(Kingman, Fort Smith, Oakland)
400 participants
University of Rochester NCORP Research Base
View Study Details
RecruitingNCT05138133

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis...

10 locations(Birmingham, Glendale, La Jolla)
360 participants
AstraZeneca
View Study Details
RecruitingNCT06411249

A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ...

10 locations(Anniston, Flagstaff, Mesa)
350 participants
GlaxoSmithKline
View Study Details
RecruitingNCT06456567

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)

The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE....

4 locations(Hemet, Menifee, Rockford)
350 participants
RemeGen Co., Ltd.
View Study Details
RecruitingNCT05799378

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms. Despite a...

10 locations(Los Angeles, Hackensack, New York)
330 participants
NYU Langone Health
View Study Details
RecruitingNCT00775476

Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack ...

8 locations(Los Angeles, New Haven, New York)
290 participants
State University of New York - Upstate Medical University
View Study Details
RecruitingNCT05624749

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants wi...

10 locations(Anniston, Irvine, La Palma)
280 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNCT05268289

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment....

10 locations(Phoenix, Fontana, Irvine)
240 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNCT06043440

Down Syndrome Obstructive Sleep Apnea

The purpose of this study is to assess whether oxygen supplementation during sleep improves working memory and other clinical and patient-reported outcomes among children who have Down Syndrome (DS) w...

7 locations(Los Angeles, Ann Arbor, Cincinnati)
230 participants
Brigham and Women's Hospital
View Study Details
RecruitingNCT05559671

Safety of the Herpes Zoster Subunit Vaccine in Lupus

This randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity...

2 locations(New York, Oklahoma City)
224 participants
NYU Langone Health
View Study Details
RecruitingNCT06559163

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE)....

10 locations(Fresno, Huntington Park, La Jolla)
190 participants
Zenas BioPharma (USA), LLC
View Study Details
RecruitingNCT03642028

Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress

Post-traumatic stress disorder (PTSD) is a common consequence of combat that can result in trauma-related hyperarousal and sleep disturbances. Poor sleep, one of the most common complaints in Veterans...

4 locations(Long Beach, San Francisco, Salisbury)
190 participants
VA Office of Research and Development
View Study Details
RecruitingNCT05612594

Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study

The goal of this clinical trial is to test if bexagliflozin lowers the sleep apnea severity in adults who are overweight or obese with moderate to severe obstructive sleep apnea (OSA) compared with a ...

2 locations(New Haven, Cleveland)
164 participants
Yale University
View Study Details
RecruitingNCT05953610

Endotypic Traits and Obstructive Sleep Apnea Surgery

This study will examine factors associated with outcomes after soft palate surgery and medications (acetazolamide, eszopiclone) that may treat other potential causes of obstructive sleep apnea (loop g...

2 locations(Santa Monica, Westwood, Los Angeles)
150 participants
University of California, Los Angeles
View Study Details
RecruitingNCT06897930

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants wit...

5 locations(Bethesda, New York, Syracuse)
150 participants
AstraZeneca
View Study Details
RecruitingNCT06581198

A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN)

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus ...

10 locations(San Francisco, San Francisco, San Pablo)
144 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNCT04092894

Suvorexant and Sleep/Delirium in ICU Patients

Investigators will evaluate the efficacy of postoperative oral suvorexant treatment on nighttime wakefulness after persistent sleep onset (WASO) among adult cardiac surgical patients recovering in the...

2 locations(Boston, The Bronx)
120 participants
Beth Israel Deaconess Medical Center
View Study Details
RecruitingNCT05039840

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatm...

10 locations(Birmingham, Chandler, Mesa)
116 participants
Sanofi
View Study Details
RecruitingNCT05538208

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

The study is a 1-year 2-part double-blinded placebo controlled 2-arm clinical trial. Treatment arms are (1) MMF dosed as per body-surface area (MMFBSA; 600mg/m2 body surface area per dose about every ...

10 locations(San Francisco, Aurora, Atlanta)
105 participants
Children's Hospital Medical Center, Cincinnati
View Study Details
RecruitingNCT05835310

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

A Study to evaluate the PK, PD, efficacy, and safety of Anifrolumab in children with moderate to severe active SLE...

10 locations(Phoenix, Los Angeles, Washington D.C.)
100 participants
AstraZeneca
View Study Details
RecruitingNCT06570798

A Phase 2a Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to as...

10 locations(Scottsdale, Aurora, Hialeah)
98 participants
Amgen
View Study Details
RecruitingNCT07015983

A Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate respo...

10 locations(Birmingham, Los Angeles, Los Angeles)
89 participants
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
View Study Details
RecruitingNCT06649929

Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples With Implications for Alzheimer's Disease Risk

The goal of this clinical trial is to learn if the culturally adapted couples sleep health intervention (Nuestro Sueno) improves positive airway pressure use and sleep among Hispanic couples in which ...

2 locations(Tucson, Salt Lake City)
80 participants
University of Utah
View Study Details
RecruitingNCT05201469

VIBRANT: VIB4920 for Active Lupus Nephritis

This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in parti...

10 locations(La Jolla, Los Angeles, Orange)
74 participants
National Institute of Allergy and Infectious Diseases (NIAID)
View Study Details
RecruitingNCT04652882

Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)

This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female participants with DSWPD....

10 locations(Los Angeles, Redwood City, Aurora)
70 participants
Vanda Pharmaceuticals
View Study Details
RecruitingNCT06776432

Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea

The primary purpose of this study is to evaluate the effectiveness of sivopixant, acetazolamide and SASS-001 in adults with sleep apnea with a central component....

8 locations(La Jolla, Brandon, Miami)
60 participants
Shionogi Apnimed Sleep Science
View Study Details
RecruitingNCT06980805

A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of IMVT-1402 in participants with Cutaneous Lupus Erythematosus. The study will consist of 3 periods: Period 1...

10 locations(Anniston, Birmingham, Phoenix)
56 participants
Immunovant Sciences GmbH
View Study Details
RecruitingNCT05288855

Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis

The purpose of this study is to assess the efficacy and safety of voclosporin compared to placebo in achieving renal response following 24 weeks of therapy in adolescent and pediatric subjects with ac...

7 locations(Orlando, Chapel Hill, Barranquilla)
40 participants
Aurinia Pharmaceuticals Inc.
View Study Details
RecruitingNCT05039619

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less...

10 locations(Loma Linda, San Francisco, Aurora)
40 participants
Hoffmann-La Roche
View Study Details
RecruitingNCT06785454

A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

The primary purpose of the study is to assess the effect of lorundrostat taken orally (po) once a day on the Apnea-Hypopnea Index (AHI) in participants with moderate to severe obstructive sleep apnea ...

10 locations(Tuscaloosa, Chandler, Little Rock)
40 participants
Mineralys Therapeutics Inc.
View Study Details
RecruitingNCT06875960

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (...

3 locations(Farmington, New York, Jackson)
35 participants
Bristol-Myers Squibb
View Study Details
RecruitingNCT05629208

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information on what is ha...

10 locations(Phoenix, Fremont, La Jolla)
33 participants
Gilead Sciences
View Study Details
RecruitingNCT05938725

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis...

6 locations(Palo Alto, Denver, Worcester)
32 participants
Kyverna Therapeutics
View Study Details
RecruitingNCT06064929

A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old

In this study, researchers will learn more about the use of felzartamab in people with active lupus nephritis, also known as LN. In people with LN, antibodies build up in the glomeruli of the kidneys....

10 locations(Mesa, La Jolla, San Francisco)
20 participants
HI-Bio, A Biogen Company
View Study Details
RecruitingNCT06121297

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus...

10 locations(Orange, Sacramento, New Haven)
12 participants
Cabaletta Bio
View Study Details

Top Cities for Lupus Clinical Trials

Lupus clinical trials are recruiting across 162 cities. Here are the cities with the most active studies:

About Lupus

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect the joints, skin, kidneys, brain, and other organs. It is more common in women and often involves periods of flares and remission. Treatment includes antimalarials, immunosuppressants, and biologics.

Clinical trials are advancing new treatments for lupus. Currently, 48 studies are recruiting a combined 11,922 participants across the United States. Research is being conducted by 34 organizations including AbbVie, Novartis Pharmaceuticals, Biogen and 31 others.

2026 Lupus Research Landscape

As of March 2026, the lupus clinical trial landscape includes 48 actively recruiting studies across 162 cities in the United States. These studies are collectively seeking 11,922 participants, with an average enrollment target of 248 per study.

Research is being led by 34 different organizations, including AbbVie, Novartis Pharmaceuticals, Biogen, Bristol-Myers Squibb, AstraZeneca, and 29 others. The large number of sponsors reflects significant research interest and investment in lupus treatment advancement.

Geographically, lupus trials are most concentrated in Los Angeles, California (23 trials); Aurora, Colorado (12 trials); La Jolla, California (12 trials); New York, New York (12 trials); Phoenix, Arizona (11 trials) and 7 other cities.

Featured Lupus Studies

Highlighted recruiting studies for lupus, selected by enrollment size and research scope.

RecruitingNCT05843643

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthriti...

Sponsor: AbbVie· 1,000 participants· 10 locations (Chandler, Flagstaff, Gilbert, Glendale)
View full study details →
RecruitingNCT06133972

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).

Sponsor: Novartis Pharmaceuticals· 550 participants· 10 locations (Anniston, La Palma, Westlake Village, Clearwater)
View full study details →
RecruitingNCT04895241

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. The main objective of the study is to learn about the effect litifilim...

Sponsor: Biogen· 540 participants· 10 locations (Homewood, Beverly Hills, Los Angeles, Mission Hills)
View full study details →

Frequently Asked Questions About Lupus Clinical Trials

Are there lupus clinical trials near me?

Yes, there are 48 lupus clinical trials currently recruiting across 162+ cities in the United States, including Los Angeles, California; Aurora, Colorado; La Jolla, California. Browse the studies above to find one at a location convenient for you.

How do I join a lupus clinical trial?

To join a lupus clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.

Are lupus clinical trials free?

Yes, participation in lupus clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.

What types of lupus treatments are being studied?

Current lupus clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 34 research organizations.

Is it safe to participate in lupus clinical trials?

Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.

Data updated March 1, 2026 from ClinicalTrials.gov

About This Data

Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.

Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.

Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov